Z. Wang

TL;DR: The use of everolimus with progressive reduction in CsA exposure, up to 60% at 1 year, resulted in similar efficacy and renal function compared with standard‐exposure Cs a plus MPA.

TL;DR: Everolimus trough concentrations targeted to 3–8 ng/mL, along with a greater than 60% reduction in CsA exposure, was associated with comparable efficacy and renal function versus MPA plus standard-exposure Cs a over the 2-year period.

TL;DR: Conversion to everolimus at 10–14 weeks posttransplant was associated with renal function similar to that with standard therapy overall, and reporting on de novo donor‐specific antibodies (DSA) was limited but suggested more frequent anti‐HLA Class I DSA underEverolimus.

TL;DR: The association between clinical events and everolimus exposure in patients receiving reduced‐exposure calcineurin inhibitor therapy is poorly explored.

TL;DR: Data from the open-label ELEVATE trial do not suggest a clinically relevant effect on cardiac end points after early conversion from CNI to a CNI-free everolimus-based regimen.